By Stephen Nakrosis
Galapagos NV said Paul Stoffels, the company's chair and chief executive officer, intends to retire as CEO upon appointment of a successor, but plans to continue serving as chair.
The board will search for a successor to Stoffels, with the successor CEO expected to be hired in the next 12 months.
The company also said Henry Gosebruch, who was most recently president and CEO at Neumora, was appointed by the board to serve as the founding CEO of a newly created company which will be spun off. The new company will initially be funded with about EUR2.45 billion ($2.81 billion) in cash and cash equivalents. The new company will focus on building a pipeline of "innovative medicines with demonstrated proof-of-concept and the potential to elevate standard-of-care for patients through one or more transformative transactions," according to Galapagos.
Prior to Neumora, Gosebruch was EVP and chief strategy officer at AbbVie, and before that worked at J.P. Morgan, Galapagos said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 21, 2025 16:53 ET (20:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。